ECOR

ROCKAWAY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, taking place on Wednesday, November 11, 2026, at The Westin New York Grand Central in New York City.

electroCore, Inc. (ECOR) Q3 2026 Earnings Call Transcript

Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million  in the third quarter of 2025 Net loss of $1.3 million decreased 61% from prior year with Adjusted EBITDA net loss improving 67% from prior-year period Company to host a conference call and webcast today, November 4, 2026, at 4:30 pm EST ROCKAWAY, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced financial results for the third quarter ended September 30, 2026.

ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026.

Joshua Lev, co-CEO, president and CFO of electroCore NASDAQ: ECOR, said the commercial-stage bioelectronic health and wellness company is seeking to broaden its federal-market presence, expand product indications and reach adjusted EBITDA profitability in the second half of 2027.

ROCKAWAY, N.J.,, Oct. 27, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced findings presented by the United States Air Force Research Laboratory (AFRL) of a controlled functional magnetic resonance imaging (fMRI) study evaluating transcutaneous cervical vagus nerve stimulation (tcVNS) during complex visual skill learning.

ROCKAWAY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at Planet MicroCap Toronto 2026 Powered by MicroCapClub being held at the Arcadian Court & Loft.

electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ROCKAWAY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the H.C.

ROCKAWAY, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, effective September 8, 2026.